Edward Nash
Stock Analyst at Canaccord Genuity
(4.38)
# 325
Out of 4,902 analysts
82
Total ratings
49.3%
Success rate
23.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Downgrades: Hold | $107 | $104.78 | +2.12% | 10 | Jul 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $394 → $420 | $348.73 | +20.44% | 9 | May 2, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $64 | $22.97 | +178.62% | 1 | Apr 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $16.51 | +184.68% | 10 | Apr 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $130 → $142 | $73.10 | +94.25% | 7 | Apr 1, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.42 | +2,058.79% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.42 | +181.69% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $54.33 | +34.36% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $39.00 | +128.21% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $3.27 | +328.13% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.19 | +572.27% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $3.26 | +513.38% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $3.15 | +154.37% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $5.54 | +206.86% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.12 | -5.66% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $2.33 | +7,625.32% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $27.41 | +199.16% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.84 | +2,716.90% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $15.20 | +215.79% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $6.63 | +9,703.92% | 1 | Nov 8, 2017 |
Verona Pharma
Jul 9, 2025
Downgrades: Hold
Price Target: $107
Current: $104.78
Upside: +2.12%
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $394 → $420
Current: $348.73
Upside: +20.44%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $22.97
Upside: +178.62%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $16.51
Upside: +184.68%
Corcept Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $130 → $142
Current: $73.10
Upside: +94.25%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.42
Upside: +2,058.79%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.42
Upside: +181.69%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $54.33
Upside: +34.36%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $39.00
Upside: +128.21%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $3.27
Upside: +328.13%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.19
Upside: +572.27%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.26
Upside: +513.38%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $3.15
Upside: +154.37%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $5.54
Upside: +206.86%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.12
Upside: -5.66%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $2.33
Upside: +7,625.32%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $27.41
Upside: +199.16%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.84
Upside: +2,716.90%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $15.20
Upside: +215.79%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $6.63
Upside: +9,703.92%